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term cost-effectiveness is evaluated using a 12-month treatment period with ti-
cagrelor versus clopidogrel in patients with ACS based on PLATO trial data from the
Mexican public and private perspective. METHODS: The cost-effectiveness model
is divided into two parts: a short-term decision tree based on data from the PLATO
trial to estimate rates of cardiovascular events, healthcare costs, and health-re-
lated quality of life for the 12 months of therapy and a long-term Markov model to
estimate quality-adjusted survival and costs conditional on whether a non-fatal
MI, a non-fatal stroke or no MI or stroke occurred during the 12 months of therapy.
Costs were calculated by applying 2010 Mexican unit costs. The daily drug price
used was $2.05 and $4.91 for clopidogrel and ticagrelor, respectively. The estimated
mean costs and QALYs are calculated over a lifetime time horizon and presented as
incremental cost per QALY. Probabilistic sensitivity analyses were performed.
RESULTS: Ticagrelor was associated with a QALY gain of 0.10; this was primarily
driven by lower mortality and fewer non fatal MI’s resulting in an incremental cost
per QALY gained of $7670 and $7073 for the public and private healthcare sector,
respectively. Probabilistic sensitivity analysis indicated that ticagrelor has more
than 99% probability of being more cost-effective than clopidogrel at a willingness
to pay of $30,000 per QALY. The results were consistent in all ACS subgroups.
CONCLUSIONS: Ticagrelor  aspirin is a cost effective treatment compared to
clopidogrel  aspirin for one year treatment in ACS patients based on the PLATO
trial and Mexican unit costs.
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Recently, ticagrelor showed a statistically significant absolute reduction (1.1%/
year) in cardiovascular (CV) mortality and in myocardial infarction (MI) (1.1%/year)
compared to clopidogrel in acute coronary syndrome (ACS) patients (from pub-
lished results of the PLATO trial). The majority of earlier ACS trials (including CURE
- placebo vs. clopidogrel and TRITON - clopidogrel vs. prasugrel) have not shown
this significant reduction in CV mortality. OBJECTIVES: To estimate the cost-effec-
tiveness of 1-year add-on therapy to aspirin with ticagrelor versus clopidogrel in
patients with ACS in the Dutch setting, based on the published results from PLATO.
METHODS: A published Markov cost-effectiveness model with MI, stroke, death
and subsequent events as health states is used to assess the cost-effectiveness of
ticagrelor in comparison to clopidogrel. In the model relevant utilities and costs are
linked to the health states. Short-term probabilities are based on the published
PLATO trial, while probabilities for subsequent events are assumed to change with
time and occurring events. Several sources were used for these extrapolations. The
cost-effectiveness was tested over daily acquisition cost of ticagrelor varying be-
tween €1 and €7 higher than clopidogrel. Relevant discount rates were applied and
probabilistic sensitivity analyses were conducted. RESULTS: Considering direct
medical costs only, the incremental cost-effectiveness ratios (ICERS) when the cost
of ticagrelor is assumed to be €1, €3, €5, and €7 higher than clopidogrel per day are
estimated at €3,742/QALY, €12,058/QALY, €20,374/QALY, and €28,691/QALY respec-
tively. Probabilistic sensitivity analyses show that ticagrelor is expected to be cost-
effective at a willingness to pay of €30,000 in 100.0%, 98.2%, 89.4%, and 58.0% of
cases when the price is assumed to be €1, €3, €5, or €7 higher than clopidogrel per
day, respectively. CONCLUSIONS: The reduction in mortality seen in the PLATO
trial translates to favorable cost-effectiveness results for ticagrelor, assuming the
price difference over clopidogrel does not exceed €7.50 per day.
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OBJECTIVES: The PLATO trial was a multicentre, double-blind, randomized trial
comparing clopidogrel  aspirin and ticagrelor  aspirin for treatment of patients
with ST-elevation and non-ST-elevation acute coronary syndromes (ACS). The re-
sults showed a significant reduction for ticagrelor in the primary composite end-
point – cardiovascular deaths, myocardial infarction, or stroke - without a signifi-
cant increase in major bleeding. Based on PLATO trial data long-term cost-
effectiveness was evaluated for 12-month treatment with ticagrelor versus
clopidogrel in patients with ACS, from the Brazilian public health care perspective.
METHODS: For the analysis of cost-effectiveness a two-part cost-effectiveness
model was used. The first part was a 12-month decision tree using PLATO trial data
to estimate rates of cardiovascular events, healthcare costs, and health-related
quality of life for the 12 months of therapy. The second part was a long-term
Markov model estimating quality-adjusted survival and costs conditional on
whether a non-fatal MI, a non-fatal stroke, or no MI or stroke occurred during the 12
months treatment. The model applied a lifetime horizon to calculate mean costs
and QALYs. The results are presented as incremental cost-effectiveness ratios (IC-
ER’s). Daily costs of $1.62 for generic clopidogrel and $4.58 for ticagrelor were ap-
plied. Other costs were calculated by applying Brazilian year 2010 unit costs. Prob-
abilistic sensitivity analysis was performed. RESULTS: Ticagrelor was associated
with a QALY gain of 0.10, primarily driven by lower cardiovascular mortality. The
resulting incremental cost per QALY gained was $8966 in the public sector. Proba-
bilistic sensitivity analysis indicated that ticagrelor had more than 99% probability
of being cost-effective at a willingness to pay of $30,000 per QALY. The results were
consistent in all analyzed subgroups. CONCLUSIONS: Based on the PLATO trial
data one year treatment with ticagrelor  aspirin versus clopidogrel  aspirin in
ACS patients is cost-effective from a Brazilian public health care perspective.
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OBJECTIVES: To evaluate the long term cost-effectiveness of rosuvastatin versus
generic atorvastatin in the treatment of patients at high cardiovascular risk (CVR)
5% SCORE or patients with established cardiovascular disease in Spain.METHODS:
The efficacy data from STELLAR trial (Statin Therapies for Elevated Lipid Levels
compared Across doses to Rosuvastatin) was used to simulate cLDL goal attain-
ment at different doses of rosuvastatin and generic atorvastatin during an initial
period of one year. These results were combined in the long term through a Markov
model which estimated the number of cardiovascular events and their impact on
quality of life in patients at high CVR using the Framingham risk equations. The
model estimated quality adjusted life years (QALY) and costs (drug and events
costs) up to 20 years. The analysis was conducted from the Spanish National Health
System perspective. 3% annual discount rate was applied to costs (€ 2010) and
outcomes. Cost-effectiveness was estimated in several subgroups of patients at
high CVR according to blood pressure, smoking status, age, cholesterol levels and
established cardiovascular disease. RESULTS: In primary prevention of cardiovas-
cular events in patients at high risk, rosuvastatin was a cost-effective option (cost/
QALY less than €30,000) versus generic atorvastatin in most of the subgroups ana-
lyzed. In patients with established cardiovascular disease, rosuvastatin was a cost-
effective option in all males subgroups (ICERs between €4,000 and €18,000 per
QALY) and in most of the females subgroups. CONCLUSIONS: The treatment of
patients at high cardiovascular risk with rosuvastatin was more effective than
generic atorvastatin in terms of survival and quality adjusted survival. Incremental
cost-effectiveness ratios were below the commonly accepted efficiency threshold
in Spain (€30,000) in most of the defined subpopulations by different combination
of risk factors.
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OBJECTIVES: 1) To estimate the time and cost of discharge for patients receiving
the current antithrombotic standard of care, warfarin / a heparin product at a
large US academic medical center, and 2) to estimate the system-level impact of a
hypothetical new oral antithrombotic in terms of improved discharge efficiency.
METHODS: Data were obtained from 2010 institutional metrics: patient volume,
major diagnoses (e.g., orthopedic surgery, atrial fibrillation), and resource require-
ments (time and cost of personnel providing antithrombotic discharge counseling;
time and cost of INR-related discharge delays). Metrics were coded as inputs in a
MS Excel model to estimate the potential time and cost impact of changes in pa-
tient volume, personnel providing counseling, or addition of novel oral agents to
the formulary. It was assumed that 80% of warfarin patients would receive the
novel antithrombotic, that these drugs would reduce discharge counseling time by
70%, and would not require INR testing. The cost per day of the new agent was
assumed to be $7 versus $0.82 for warfarin, and the bed of discharged patients was
assumed to be refilled with a new patient 100% of the time at a reimbursement rate
of $1500/day. RESULTS: Based on 1000 patients with a LOS of 4 days, efficiency
impacts of the new agent were estimated as follows: 4000 hours through avoidance
of INR-related delays, 400 hours through elimination of delayed discharge coun-
seling, 284 hours in reduced time to administer discharge counseling. Total patient
days saved by the new drug were 142 per year, translating to $213,000 in revenue
opportunity by improving the efficiency of the discharge process. Additional drug
costs to the facility were estimated to be $19,776 assuming drug prices and patient
volume are consistent with model inputs. CONCLUSIONS: The model quantifies
the system-level impact of new oral antithrombotics and informs formulary deci-
sion making.
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OBJECTIVES: To compare the efficiency of three strategies for the stenosis of the
femoropopliteal sector treatment: bypass surgery (BP), percutaneous transluminal
angioplasty with selective stent insertion (PTA/S), and percutaneous transluminal
angioplasty with selective stent insertion followed by possible bypass surgical re-
intervention (PTA/S/BP). METHODS: An economic evaluation was developed by
implementing a Markov model with three main branches representing each of the
strategies studied. We used a time horizon of 30 years, discounting 3% to costs and
effects. The measure of effectiveness was years of quality-adjusted life (QALYs).
Probabilistic and multivariate sensitivity analysis was performed by using Monte
Carlo (MC) methods. Acceptability curves and the expected value of perfect infor-
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mation were calculated. RESULTS: Taking into account the results from MC simu-
lations, the PTA/S alternative is the most expensive and less effective (€ 24,581 and
6.857 QALYs), but attending to small differences and the large variability on results
between alternatives, these results are not conclusive. The least costly alternative
is PTA/S/BP (€ 18,351), with an effectiveness of 7.049 QALYs. PTA/S/BP shows higher
effectiveness than PTA/S, but lower effectiveness than BP (7.281 QALYs). The cost of
the BP alternative is € 24,056. PTA/S/BP and BP alternatives show higher probabili-
ties of being efficient alternatives. If the willingness to pay is € 30,000/QALY, op-
portunity cost of implementing PTA/S/BP would exceed € 15,000 per patient
treated. CONCLUSIONS: Although the results of effectiveness identified PTA/S/BP
as the most efficient alternative for a willingness to pay less than € 40,000/QALY,
the probability of making a proper decision is only about 50%. This situation, to-
gether with the high opportunity costs, encourages the development of new clin-
ical trials or observational studies in our environment in order to remove uncer-
tainty over the results.
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OBJECTIVES: Ranolazine is an antianginal agent that was approved for use in the
EU in 2008 as an add-on therapy for the symptomatic treatment of chronic angina
pectoris in patients who are inadequately controlled by or intolerant to first-line
antianginal therapies, such as beta blockers and calcium antagonists. The objective
of this study is to assess the cost utility of ranolazine relative to placebo as an
add-on therapy for the symptomatic treatment of patients with chronic angina
pectoris in Spain, from the payer’s perspective. METHODS: We use a decision tree
model with a time horizon of one year, under the Spanish health service perspec-
tive. Transition probabilities and utility levels for different angina frequencies were
obtained from published clinical trials. Costs were obtained from Spanish official
DRGs for patients with chronic angina pectoris. We calculate the incremental cost
utility ratio of using ranolazine compared with placebo as an add-on treatment.
Sensitivity analyses include Monte Carlo simulations and ANCOVA models.
RESULTS: The incremental cost utility ratio is 8455 € per QALY per patient in Spain.
Sensitivity analyses show that if the decision makers= willingness to pay is set at
half the usual threshold (15.000 € per QALY), the treatment with ranolazine will be
cost effective at a 95% level of confidence. The incremental cost utility ratio is
particularly sensitive to changes in the level of utility of those non hospitalized
patients with mild or moderate angina frequency. The cost of ranolazine explains
6.44% of the variation in our results. CONCLUSIONS: Ranolazine is a very cost
effective add-on therapy for the symptomatic treatment of chronic angina pectoris
in patients who are inadequately controlled by or intolerant to first-line antianginal
therapies in Spain.
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OBJECTIVES: Cardiovascular disease is a major cause of illness and death. The
polypill seems to offer a promising strategy in the prevention of cardiovascular
diseases. The aim of the present study was to estimate the cost-effectiveness of the
polypill in the primary prevention of cardiovascular diseases in people at a 10 years
risk of cardiovascular death of 5%, 7,5% and 10% or above in the The Netherlands.
METHODS: A computer simulation study was conducted, in which people eligible
for prescription were identified by opportunistic screening. The polypill was of-
fered in different compositions: scenario 1: the polypill as used in the Indian poly-
cap study, with three different types of blood pressure lowering drugs, a lipid
lowering drug, and an antiplatelet agent, scenario 2: as 1) but without aspirin,
scenario 3: as 2) but with a double statin dose (which is the standard in The Neth-
erlands), and scenario 4: separate antihypertensive and/or statin medication. Out-
come measures were cases of acute myocardial infarction and stroke prevented,
QALYs gained, and the costs per QALY gained. RESULTS: All scenarios are cost-
effective with an incremental cost-effectiveness ratio between €8,700-12,000 per
QALY compared with usual care. The most preferable is scenario 3, because for all
risk thresholds most health gain was reached. At a 10-years risk of 7.5% scenario 3
would prevent approximately 3%-5% of all cardiovascular events. CONCLUSIONS:
Depending on the cardiovascular risk, opportunistic screening in combination with
the polypill or separate medication offers a cost-effective strategy. Most health
gain is achieved by the polypill without aspirin and a double statin dose. The major
advantage of a polypill without aspirin is avoiding aspirin’s adverse effects.
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OBJECTIVES: To assess the cost-effectiveness of the anti-arrhythmic agent drone-
darone for the prevention of cardiovascular disease (CVD, comprising myocardial
infarction and stroke) and death among Australian patients with atrial fibrillation
(AF). METHODS: A Markov model was developed with one-year cycles and three
health states: ‘Alive without CVD’, ‘Alive post CVD’ and ‘Dead’. Model subjects’
cardiovascular and mortality risks were derived from a cohort study of 313 AF
patients from the Geelong Hospital, a tertiary hospital in Victoria, Australia. Deci-
sion analysis quantified the health and economic effects of giving all patients
dronedarone versus usual care. Data regarding the efficacy of dronedarone were
derived from the two-year ‘ATHENA’ randomized controlled trial (Hohnlosser, New
Engl J Med, 2009). This showed that compared to placebo, dronedarone 400mg bd
reduced the risk of hospitalized cardiovascular events and death by 24% (hazard
ratio 0.76, 95%CI 0.69-0.84). Relevant costs and utilities were drawn from published
sources. The annual cost of dronedarone was AUD $1668. Follow-up was simulated
for ten years, with application of a 5% annual discount rate to costs and years lived.
RESULTS: In the usual care arm, 26.3% and 12.0% of the cohort were predicted to
suffer myocardial infarctions and strokes, respectively. The equivalent figures in
the dronedarone arm were 21.4% and 9.7%, equating to numbers needed to treat of
20.3 for myocardial infarction and 44.6 for stroke. Compared to usual care, each
dronedarone subject lived an extra 0.44 years and 0.35 QALYs (discounted). Net
costs of dronedarone amounted to AUD $4495 per subject (discounted). Incremen-
tal cost-effectiveness ratios were therefore AUD $10,187 per life year gained and
AUD $12,966 per QALY gained. Sensitivity analyses indicated the results to be
robust. CONCLUSIONS: Dronedarone represents a cost-effective means to prevent
downstream cardiovascular morbidity and mortality among Australian patients
with AF.
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PRESSURE IN NIGERIAN HOSPITALS
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OBJECTIVES: Emerging evidence shows that the prevalence of hypertension is on
the rise in most African countries while control remains poor. There are effective
interventions which could be implemented in hospitals of low resource setting to
improve control of blood pressure amongst hypertensive patients. This study
aimed to evaluate the cost-effectiveness of interventions that could be imple-
mented in Nigerian hospitals in order to ensure better control of high blood pres-
sure in patients with hypertension. METHODS: The study employed decision ana-
lytic modeling. Interventions were obtained from a meta-analysis. The Markov
process model calculated clinical outcomes and costs during a life cycle of 30 years
of 1000 hypertensives stratified by 3 cardiovascular risk groups, under the alterna-
tive intervention scenarios. Quality adjusted life year (QALY) was used to quantify
clinical outcome. The average cost of treatment for the 1000 patient was tracked
over the Markov cycle model of the alternative interventions and results were
presented in Nigerian Naira. Probabilistic cost-effectiveness analysis was per-
formed using Monte Carlo simulation, and results presented as cost-effectiveness
acceptability curves and frontiers. Population expected value of perfect informa-
tion analysis was also conducted. RESULTS: Patient education intervention was
the most cost-effective option across the 3 cardiovascular risk groups except in
high cardiovascular risk scenario where a trade-off has to be made in terms of
commitment of extra fund (approximately N10,000 per QALY). Professional led care
was the second best consistent option across the 3 cardiovascular risk groups
although it will require extra financial investment to the tune of N30,000 per QALY.
CONCLUSIONS: The result of this study shows that patient education programme
followed by professional led care intervention could be a feasible strategy in order
to ensure that patients with high blood pressure are better controlled.
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OBJECTIVES: To evaluate the economic efficiency of 10-years cardiovascular pre-
vention program in primary care of Russian Federation.METHODS: In 1977-1990 in
Moscow a large prevention project was realized. The project was realized in two
primary care areas of Moscow and included men with baseline age 40-59. One
primary care area was intervention area where cardiovascular prevention program
was realized during the 5 years, other area was control. Participants of intervention
(n3488) and control primary care areas (n3168) had the similar age, education
and cardiovascular morbidity. The cardiovascular prevention program included
preventive counseling for participants with CVD risk factors. All cardiovascular
endpoints were registered during 10 years. In this study we calculated the gain of
life years saved (LYS) and quality adjusted life years (QALY) in intervention group
compared with control group (on 1000 participants) during the 5 years on the in-
tervention and during 10 years of total follow up period. Also we calculate the total
cost of the program in the prices of 2008 years. The cost utility analysis was con-
ducted with calculation of cost per gained QALY during 5 years and during 10 year.
RESULTS: The number of gained LYS in the intervention group was 45.7 on 1000
participants in 5 years and 139.4 – in 10 years. The number of QALY was 46.2 and
132.7 on 1000 participants in 5 and 10 years accordingly. The total costs were
174,124$ on 1000 participant in 5 years and 237,928$ in 10 years. Cost per QALY
gained was 3769$ during the 5 years and 1793$ during the 5 years. The gross do-
mestic product per capita in 2008 was 11,806$. CONCLUSIONS: Cardiovascular
prevention program for men aged 40-59 is highly cost-effective and economic ar-
guments can be used for policy-makers.
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